PHASE 2B TRIALS
We have successfully completed phase 2b trial in BCCNS. Within that clinical trial we treated 447 basal cell carcinomas in 38 patients with an ORR for individual tumors >50%. The drug was well tolerated and demonstrated prolonged progression free survival. Only fifteen of the 447 (3%) target lesions increased in size during time on study with only 4 of 447 (0.01%) increasing by ≥ 20%.
From the Gorlin Syndrome Aliance Patient Forum:
“I am participating in the clinical trial for the itraconazole. It is working very well for me (75% of the targeted spots are either gone or greatly reduced). And I have not had any side effects”.
